About DermBiont
DermBiont is a company based in Melrose (United States) founded in 2015 by Nichola Eliovits. DermBiont has raised $78.91 million across 8 funding rounds from investors including Illumina, Viking Global Investors and Civilization Ventures. The company has 14 employees as of December 31, 2024. DermBiont has completed 1 acquisition, including SeylanMED. DermBiont offers products and services including Pipeline Platform and Small Molecules. DermBiont operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Melrose, United States
- Employees 14 as on 31 Dec, 2024
- Founders Nichola Eliovits
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Dermbiont, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of DermBiont
DermBiont offers a comprehensive portfolio of products and services, including Pipeline Platform and Small Molecules.
Platform for advancing topical therapeutics in skin diseases
Compounds targeting root causes of dermatology conditions
People of DermBiont
Unlock access to complete
Unlock access to complete
Funding Insights of DermBiont
DermBiont has successfully raised a total of $78.91M across 8 strategic funding rounds. The most recent funding activity was a Series B round of $32.7 million completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in DermBiont
DermBiont has secured backing from 9 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Illumina, Viking Global Investors and Civilization Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private investment firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Venture capital is provided to health tech and biology innovations.
|
Locked | Locked | Locked | |
|
Provider of a venture capital firm that invests in technology and life sciences companies
|
Locked | Locked | Locked |
Investor details for DermBiont
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by DermBiont
DermBiont has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include SeylanMED.
Investment portfolio details for DermBiont
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Treatments for skin disorders are developed by the company.
|
Locked | Locked | 2016 | Locked |
Complete acquisition details for DermBiont
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - DermBiont
Detailed financials for DermBiont
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dermbiont Comparisons
Peer comparison for DermBiont
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of DermBiont
DermBiont operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
Detailed competitors of DermBiont
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dermbiont
Complete news archive for DermBiont
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DermBiont
DermBiont was founded in 2015 and raised its 1st funding round 3 years after it was founded.
DermBiont is headquartered in Melrose, United States. It is registered at Melrose, Massachusetts, United States.
DermBiont is a funded company, having raised a total of $78.91M across 8 funding rounds to date.
As of Dec 31, 2024, the latest employee count at DermBiont is 14.
DermBiont was founded in 2015 and is based in Melrose, United States. Microbial therapeutics are developed by the company to address various skin conditions within the biotechnology sector. Topical candidates include DBI-001, targeted at eczema, athletes foot, and nail fungus; DBI-002, focused on inflammatory dandruff; and SM-020, intended for benign skin tumors. Operations center on advancing these therapeutic options through research and development.
DermBiont's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
DermBiont offers Pipeline Platform and Small Molecules.
DermBiont has made 1 acquisition, including SeylanMED.
DermBiont has 9 investors. Key investors include Illumina, Viking Global Investors, Civilization Ventures, Olive Tree Capital, and Double Point Ventures.